Lista de obras -

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of GS-9450 in Subjects With Nonalcoholic Steatohepatitis ⬇️

artículo científico publicado el 14 de diciembre de 2011

A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.

artículo científico publicado en 2017

A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease

artículo científico publicado en 2016

Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver

artículo científico publicado en 2015

Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

scientific article published on 19 July 2018

Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study

artículo científico publicado en 2018

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.

artículo científico publicado en 2017

Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design

scientific article published on 24 December 2019

Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH).

artículo científico publicado en 2017

De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation

artículo científico publicado en 2017

Derivation and analysis of viscoelastic properties in human liver: impact of frequency on fibrosis and steatosis staging.

artículo científico publicado en 2015

Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis.

artículo científico publicado en 2017

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

artículo científico publicado en 2016

Expression of mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver injury

artículo científico publicado en 2019

Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis

scientific article published on 15 September 2018

Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

artículo científico publicado en 2018

Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.

artículo científico publicado en 2014

Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.

artículo científico publicado en 2013

Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels

artículo científico publicado en 2019

IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients.

artículo científico publicado en 2012

Increased production of sonic hedgehog by ballooned hepatocytes ⬇️

artículo científico publicado el 5 de mayo de 2011

Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges

scientific article published on 16 July 2019

Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib

article

NAFLD: The clinical and economic burden of NAFLD: time to turn the tide.

artículo científico publicado en 2016

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

artículo científico publicado en 2018

Nonalcoholic Fatty Liver Disease

artículo científico publicado en 2016

Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis

scientific article published on 16 July 2018

PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease

artículo científico publicado en 2019

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

scientific article published on 13 December 2018

Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease

artículo científico publicado en 2017

Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox

artículo científico publicado en 2020

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

artículo científico publicado en 2019

Rectal Bleeding from a Mucous Fistula Secondary to a Dieulafoy's Lesion ⬇️

artículo científico publicado el 1 de junio de 1997

Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease

artículo científico publicado en 2013

Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis

artículo científico publicado en 2019

Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism.

artículo científico publicado en 2014

Reply

artículo científico publicado en 2017

Reply to Kim et al.

artículo científico publicado en 2017

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis

scientific article published on 08 December 2018

Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps

artículo científico publicado en 2019

Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

article

Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers

artículo científico publicado en 2015

The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options

artículo científico publicado en 2018

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

artículo científico publicado en 2019

Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity

artículo científico publicado en 2014

Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis

artículo científico publicado en 2018

Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease

artículo científico publicado en 2018

Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis.

artículo científico publicado en 2016

Lista de obras de

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of GS-9450 in Subjects With Nonalcoholic Steatohepatitis ⬇️

A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.

A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease

Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver

Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.

Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design

Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH).

De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation

Derivation and analysis of viscoelastic properties in human liver: impact of frequency on fibrosis and steatosis staging.

Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis.

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Expression of mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver injury

Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis

Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.

Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.

Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels

IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients.

Increased production of sonic hedgehog by ballooned hepatocytes ⬇️

Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges

Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib

NAFLD: The clinical and economic burden of NAFLD: time to turn the tide.

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis

PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease

Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

Rectal Bleeding from a Mucous Fistula Secondary to a Dieulafoy's Lesion ⬇️

Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease

Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis

Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism.

Reply

Reply to Kim et al.

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis

Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps

Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers

The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity

Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis

Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease

Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis.